Find Aspirin Lysinate manufacturers, exporters & distributors on PharmaCompass

Aspirin Dl-Lysine

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 1 USDMF, 4 Listed Suppliers

5 API Suppliers
1 USDMF
4 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

3 FDF Dossiers, 2 Europe, 1 Listed Dossiers

3 FDF Dossiers
2 Europe
1 Listed Dossiers

GLOBAL SALES INFORMATION

2 Finished Drug Prices

globalSalesInformation
2 Finished Drug Prices

MARKET PLACE

4 APIs

marketPlace
4 APIs

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Dl-lysine acetylsalicylate, 62952-06-1, Aspegic, Egicalm, Aspirisine, Aspidol

Molecular Formula

C₁₅H₂₂N₂O₆

Molecular Weight

326.34 g/mol

InChI Key

JJBCTCGUOQYZHK-UHFFFAOYSA-N

FDA UNII

2JJ274J145

Aspirin DL-Lysine is the lysine salt form of acetylsalicylic acid, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, antipyretic and anti-inflammatory activities. Like other NSAIDs, aspirin DL-lysine inhibits the activity of cyclooxygenase I and II, resulting in decreased formation of prostaglandins (PGs) and thromboxanes precursors. This leads to decreased PG synthesis by PG synthase. This agent also causes a decrease in the formation of thromboxane A2 synthesis by thromboxane synthase, thereby inhibiting platelet aggregation.

1 2D Structure

Aspirin Lysinate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-acetyloxybenzoic acid;2,6-diaminohexanoic acid

2.1.2 InChI

InChI=1S/C9H8O4.C6H14N2O2/c1-6(10)13-8-5-3-2-4-7(8)9(11)12;7-4-2-1-3-5(8)6(9)10/h2-5H,1H3,(H,11,12);5H,1-4,7-8H2,(H,9,10)

2.1.3 InChI Key

JJBCTCGUOQYZHK-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC(=O)OC1=CC=CC=C1C(=O)O.C(CCN)CC(C(=O)O)N

2.2 Other Identifiers

2.2.1 UNII

2JJ274J145

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Acetylsalicylic Acid Lysinate

2. Aspegic

3. Aspirin Lysinate

4. Aspirin Lysine

5. Aspiryl-polylysine

6. Aspisol

7. Asprin Dl-lysine

8. Flectadol

9. L-lysine, 2-(acetyloxy)benzoate (1:1)

10. Lysine Acetylsalicylate

11. Lysine-acetylsalicylic Acid

12. Lysine-aspirin

13. Solusprin

14. Solusprin, Monosalicylate, (dl-lys)-isomer

15. Solusprin, Monosalicylate, (l-lys)-isomer

16. Venopirin

2.3.2 Depositor-Supplied Synonyms

1. Dl-lysine Acetylsalicylate

2. 62952-06-1

3. Aspegic

4. Egicalm

5. Aspirisine

6. Aspidol

7. Solpirin

8. Venopirin

9. Vetalgine

10. Dl-lysine-acetylsalicylate

11. Flectadol

12. Laspal

13. L-lysine Acetylsalicylate

14. Lysine Acetylsalicylic Acid

15. Asl

16. Lysine Acetylsalicylate,(s)

17. Schembl25877

18. 2-acetoxybenzoic Acid (1:1)

19. Lysine Aspirin [mart.]

20. Chembl1697753

21. Dtxsid50886518

22. Bcp12010

23. Lysine Acetylsalicylate [mi]

24. Akos025402349

25. 2,6-diaminohexanoic Acid Compound With

26. Ac-8243

27. Dl-lysine Acetylsalicylate, Aldrichcpr

28. Acetylsalicylate Lysine [who-dd]

29. Ft-0670894

30. Dl-lysine Acetylsalicylate [ep Monograph]

31. 952l061

32. Q15041214

2.4 Create Date

2006-10-25

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₂₂N₂O₆
Molecular Weight	326.34 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	8
Exact Mass	326.14778643 g/mol
Monoisotopic Mass	326.14778643 g/mol
Topological Polar Surface Area	153 Å²
Heavy Atom Count	23
Formal Charge	0
Complexity	318
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Analgesics

Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)

Anti-Inflammatory Agents, Non-Steroidal

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)

Cyclooxygenase Inhibitors

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. (See all compounds classified as Cyclooxygenase Inhibitors.)

Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)

API SUPPLIERS